Experimental hyperlipidemia and the effect of NSAIDs

Experimental and Molecular Pathology

Volumn 73, Issue 2, 2002, Pages 135-138

  Kourounakis, A P ^b   Victoratos, P ^a   Peroulis, N ^a   Stefanou, N ^a   Yiangou, M ^a   Hadjipetrou, L ^a   Kourounakis, P N ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Cholesterol; Hyperlipidemia; LDL; NSAID; Rat; Triglycerides

Indexed keywords

ACETYLSALICYLIC ACID; CHOLESTEROL; DICLOFENAC; FLUFENAMIC ACID; IBUPROFEN; INDOMETACIN; ISOTONIC SOLUTION; LOW DENSITY LIPOPROTEIN; MEFENAMIC ACID; NAPROXEN; NIMESULIDE; TOLFENAMIC ACID; TRIACYLGLYCEROL; TYLOXAPOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HYPERLIPIDEMIA; MALE; NONHUMAN; RAT;

EID: 0036384281     PISSN: 00144800     EISSN: None     Source Type: Journal    
DOI: 10.1006/exmp.2002.2449     Document Type: Article

References (27)

1. Al-Rayyes, O., Ahren, B., and Floren, C. H. (1999). Enhancement of low density lipoprotein catabolism by non-steroidal anti-inflammatory drugs in cultured HepG2 cells. Eur. J. Pharmacol. 372(3), 311-318.
2. Baker, C. S., Hall, R. J., Evans, T. J., Pomerance, A., Maclouf, J., Creminon, C., Yacoub, M. H., and Polak, J. M. (1999). Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler. Thromb. Vasc. Biol. 19(3), 646-655.
3. Berliner, J. A., Navab, M., Fogelman, A. M., Frank, J. S., Demer, L. L., Edwards, P. A., Watson, A. D., and Lusis, A. J. (1995). Atherosclerosis. Basic mechanisms: Oxidation, inflammation and genetics. Circulation 91(9), 2488-2495.
4. Chrysselis, M., Rekka, A. E., and Kourounakis, P. N. (2000). Hypocholesterolemic and hypolipidemic activity of some novel morpholine derivatives with antioxidant activity. J. Med. Chem. 43, 609-612.
5. Dhawan, V., Ganguly, N. K., Majumdar, S., and Chakavarti, R. N. (1992). Effect of indomethacin on serum lipids, lipoproteins, prostaglandins and the extent and severity of atherosclerosis in rhesus monkeys. Can. J. Cardiol. 8(3), 306-312.
6. Diomede, L., Albani, D., Sottocorno, M., Donati, M. B., Bianchi, M., Fruscella, P., and Salmona, M. (2001). In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler. Thromb. Vasc. Biol. 21(8), 1327-1332.
7. Elneihoum, A. M., Falke, P., Hedblad, B., Lindgarde, F., and Ohlsson, K. (1997). Leucocyte activation in atherosclerosis: Correlation with risk factors. Atherosclerosis 131, 79-84.
8. Foxworthy, P. S., Perry, D. N., and Eacho, P. I. (1993). Induction of peroxisomal beta-oxidation by nonsteroidal anti-inflammatory drugs. Toxicol. Appl. Pharmacol. 118(2), 271-274.
9. Frolich, J. C. (1997). A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol. Sci. 18(1), 30-34.
10. Gansevoort, P. T., Heeg, J. E., Dikkeschei, F. D., de Zeeuw, D., de Jong, P. E., and Dullaart, R. F. F. (1994). Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria. Nephrol. Dial. Transplant. 9(3), 244-250.
11. Hochberg, M. C. (1989). NSAIDs mechanism and pathways of action. Hosp. Pract. 15, 185-198.
12. Inoue, I., Goto, S. I., Mizotani, K., Awata, T., Mastunaga, T., Kawai, S., Nakajima, T., Hokari, S., Komoda, T., and Katayama, S. (2000). Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of mRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci. 67(8), 863-876.
13. Jiang, C., Ting, A. T., and Seed, B. (1998). PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86.
14. Kontush, A., Finckh, B., Karton, B., Kohlschutter, A., and Beisiegel, U. (1996). Antioxidant and prooxidant activity of a-tocopherol in human plasma and low density lipoprotein. J. Lipid Res. 37, 1436-1448.
15. Kourounakis, A., Galanakis, D., Rekka, E., and Kourounakis, P. (1999). Synthesis and evaluation of novel derivatives of anti-inflammatory drugs with increased antioxidant and anti-inflammatory activities. Drug Dev. Res. 46, 9-16.
16. Kuroda, M., Tanzawa, K., Tsujita, Y., and Endo, A. (1977). Mechanism for elevation of hepatic cholesterol synthesis and serum cholesterol levels in triton WR-1339-induced hyperlipidemia. Biochim. Biophys. Acta 489(1), 119-125.
17. Lefebvre, A. M., Peinado-Onsurbe, J., Leitersdorf, I., Briggs, M. R., Paterniti, J. R., Fruchart, J. C., Fievet, C., Auwerx, J., and Staels, B. (1997). Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterioscler. Thromb. Vasc. Biol. 17(9), 1756-1764.
18. Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., and Kliewer, S. A. (1997). Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272(6), 3406-3410.
19. Masferrer, J. L., and Needleman, P. (2000). Anti-inflammatories for cardiovascular disease. Proc. Natl. Acad. Sci. USA 97(23), 12400-12401.
20. Reis, D. E., Roque, M., Dansky, H., Fallon, J. T., Badimon, J. J., Cordon-Cardo, C., Shiff, S. J., and Fisher, E. A. (2000). Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. USA 97(23), 12764-12769.
21. Rekka, E., Psarras, N., and Kourounakis, P. (1995). The involvement of Tolfenamic acid, Mefenamic acid and Nimesulide in free radical processes. Pharm. Sci. 1, 483-486.
22. Ross, R. (1999). Atherosclerosis is an inflammatory disease. Am. Heart J. 138(5 Pt. 2), S419-S420.
23. Shoenfeld, Y., Sherer, Y., and Harats, D. (2001). Atherosclerosis as an infectious inflammatory and autoimmune disease. Trends Immunol. 22(6), 293-295.
24. Stoller, D. K., Grorud, C. B., Michalek, V., and Buchwald, H. (1993). Reduction of atherosclerosis with nonsteroidal anti-inflammatory drugs. J. Surg. Res. 54(1), 7-11.
25. Vidal-Puig, A. J., Considine, R. V., Jimenez-Linan, M., Werman, A., Pories, W. J., Caro, J. F., and Flier, J. S. (1997). Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest. 99(10), 2416-2422.
26. Wojnar, R. J., Hearn, T., and Starkweather, S. (1980). Augmentation of allergic histamine release from human leukocytes by nonsteroidal anti-inflammatory-analgesic agents. J. Allergy Clin. Immunol. 66(1), 37-45.
27. Yamamoto, Y., Yin, M. J., Lin, K. M., and Gaynor, R. B. (1999). Sulindac inhibits activation of the NF-kappaB pathway. J. Biol. Chem. 274(38), 27307-27314.